Celltrion ships initial supply of Zymfentra to US

The S.Korean company's autoimmune disease treatment is scheduled to be available in the local market in March

Celltrion's Zymfentra
Celltrion's Zymfentra
Dae-Kyu Ahn 1
2024-02-29 10:37:03 powerzanic@hankyung.com
Bio & Pharma

South Korea's Celltrion Inc. announced on Wednesday that it shipped the first supply of its subcutaneous injection type of the autoimmune disease treatment Remsima SC (active ingredient infliximab, American name Zymfentra) to the US. 

The completed product shipped today will go through local logistics processes, including import clearance, transportation, and wholesale warehousing, and is expected to be available in the market from mid-March.

Celltrion plans to ship all three batches of the initial supply of Zymfentra from Wednesday until early March.

Zymfentra was developed by changing the existing intravenous injection type autoimmune disease treatment Remsima into a subcutaneous injection type, and it obtained new drug approval (NDA) from the US Food and Drug Administration (FDA) in October last year.

The product has obtained NDA in more than 50 countries worldwide, including Europe and Canada.

Write to Dae-Kyu Ahn at powerzanic@hankyung.com
#Celltrion #Remsima SC #Zymfentra #subcutaneous injection

Celltrion to deliver three treatments to Peru

Celltrion to deliver three treatments to Peru

South Korea’s Celltrion Inc. announced on Thursday that it will supply three treatments, including its blood cancer drug Truxima (rituximab) to Peru. Celltrion's Truxima secured an order in tenders conducted by both the Peruvian Ministry of Health (CENARES) and Peru Social Health Insura

Celltrion to supply Remsima SC, Yuflyma to Norway

Celltrion to supply Remsima SC, Yuflyma to Norway

South Korea's Celltrion Inc. announced on Wednesday that it will supply its autoimmune disease treatments Remsima SC (infliximab) and Yuflyma, the biosimilar of Humira to Norway. The company has won the Norwegian government's tender for autoimmune disease treatment. It will provide Remsima S

Celltrion, WuXi XDC to develop new antibody-drug conjugates

Celltrion, WuXi XDC to develop new antibody-drug conjugates

South Korea’s Celltrion Inc. has signed a business agreement with China’s WuXi XDC to jointly develop new antibody-drug conjugates (ADC). In December last year, Celltrion inked the contract development and manufacturing services (CDMO) with WuXi XDC to work on the linker and paylo

Celltrion to export three anticancer drugs to Europe

Celltrion to export three anticancer drugs to Europe

South Korea’s Celltrion Inc. announced on Thursday that it has secured supply contracts for three anticancer biosimilars in European countries including France, Italy, Belgium, and the Netherlands.The company reported successful contracts for the anticancer biosimilars Herzuma (trastuzum

Celltrion Holdings eyes Nasdaq IPO by early 2025: chairman

Celltrion Holdings eyes Nasdaq IPO by early 2025: chairman

Celltrion Group founder and Chairman Seo Jung-jin (left) speaks at J.P. Morgan Healthcare Conference (Courtesy of Celltrion) South Korean biosimilar giant Celltrion Group is planning to debut on the Nasdaq market by early 2025, founder and Chairman Seo Jung-jin said at the J.P. Morgan Healthcar
(* comment hide *}